Fernández-González Marta Julia, Radauer-Plank Anne-Catherine, Borgmann-Staudt Anja, Geiger Waldemar, Goranova Irena, Klco-Brosius Stephanie, Ralla Bernhard, Stelzer Cornelia, Wilkemeyer Ina, Balcerek Magdalena
Charité-Universitätsmedizin Berlin, Cooperation member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric Oncology and Hematology, Berlin, Germany.
Charité-Universitätsmedizin Berlin, Cooperate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Clinic for Urology, Berlin, Germany.
Cancer Manag Res. 2024 Jul 24;16:871-882. doi: 10.2147/CMAR.S460960. eCollection 2024.
This retrospective cohort study assessed semen and testicular tissue quality from adult and adolescent cancer patients who had samples cryopreserved in the Cryobank of Charité-Universitätsmedizin before and/or after cancer treatment.
Medical and cryopreservation data for all samples stored between 03/2004 and 05/2019 were collected retrospectively.
We included information on 601 samples cryopreserved from 506 cancer patients for whom oncologic treatment data were available. The majority of the samples were cryopreserved prior to cancer treatment (460/600, 77%, median 5 days before treatment). Semen quality had a predisposed reduction in those collected from adolescents with testicular and/or hematological malignancies. Analyses of the 140 (23%) samples cryopreserved after treatment initiation (median of 84 days) revealed decreased median concentration and motility following high gonadotoxic-risk treatment. Rate of oligoasthenozoospermia was comparable in samples collected prior to treatment with those provided during follow-up spermiograms within 1 year after treatment initiation (45.5% vs 45.5%). However, an increase was seen in samples collected 1-2 (9.1% to 90.9%) and 2-3 (50.0% to 100.0%) years after treatment initiation.
Cancer diagnosis and treatment may impair spermatogenesis; therefore, patient counseling prior to cancer treatment by an oncologist and/or fertility specialist is crucial.
这项回顾性队列研究评估了成年和青少年癌症患者在癌症治疗前后在夏里特大学医学中心冷冻库中冷冻保存样本的精液和睾丸组织质量。
回顾性收集了2004年3月至2019年5月期间储存的所有样本的医疗和冷冻保存数据。
我们纳入了506例癌症患者冷冻保存的601份样本的信息，这些患者有肿瘤治疗数据。大多数样本在癌症治疗前冷冻保存（460/600，77%，治疗前中位数5天）。来自患有睾丸和/或血液系统恶性肿瘤的青少年的精液质量预先降低。对治疗开始后（中位数84天）冷冻保存的140份（23%）样本的分析显示，在高性腺毒性风险治疗后，中位数浓度和活力下降。少弱畸精子症的发生率在治疗前采集的样本与治疗开始后1年内随访精液检查时提供的样本中相当（45.5%对45.5%）。然而，在治疗开始后1 - 2年（从9.1%增至90.9%）和2 - 3年（从50.0%增至100.0%）采集的样本中有所增加。
癌症诊断和治疗可能会损害精子发生；因此，肿瘤学家和/或生育专家在癌症治疗前对患者进行咨询至关重要。
